Skip to main content
Nagoya Protocol

Nagoya Protocol

Search complete. 37 mentions across 11 episodes found for "Nagoya Protocol".

Sep 17, 2026

Ravi PrasadGUEST
10:52
Then we ensure fair price to the farmer.
Ravi PrasadGUEST
10:55
There's another criteria which I strongly believe in actually, is something called being signatory to the Nagoya Protocol, where the farmer has to keep a portion of the seeds after every harvest of the plant in a seed bank.
Ravi PrasadGUEST
11:10
So the plant never gets extinct.
Ravi PrasadGUEST
11:12
Of the six odd thousand medicinal plants that exist in the Himalayas, probably over 2000 are extinct.

Unknown podcast

Episode 4 · From Field to Feedstock - Cultivation, Sourcing & Sustainability

Sep 17 · 8 Mentions

speaker_1HOST
2:47
They are staring down the barrel of international biodiversity law.
speaker_0HOST
2:50
Yeah, specifically the Nagoya Protocol and the whole legacy of bioprospecting.
speaker_0HOST
2:55
Developing this drug means navigating a collision between chemistry, agronomy, and anti-colonial legal frameworks.
speaker_1HOST
3:02
It's fascinating.

12 MINS LATER

speaker_1HOST
15:17
It is.
speaker_1HOST
15:18
And to combat that dynamic, we have to look at the international legal frameworks governing biological resources.
speaker_0HOST
15:23
Specifically, the Convention on Biological Diversity, the CBD, and its supplementary agreement, the Nagoya Protocol, which Gabon ratified in 2012.
speaker_1HOST
15:32
Right.

Unknown podcast

Episode 3 · Two Roads to Ibogaine - Tabernanthe iboga vs. Voacanga africana

Sep 17 · 2 Mentions

speaker_1HOST
7:30
It essentially sealed the wild harvested root bark pipeline.
speaker_1HOST
7:34
It actually took until 2022 for Gabon to see its first legal cultivated export of the plant that was fully compliant with the Nagoya Protocol.
speaker_0HOST
7:42
OK, let's define that for the listener really quick.
speaker_0HOST
7:44
The Nagoya Protocol is the international framework governing the fair and equitable sharing of benefits arising from genetic resources.
speaker_1HOST
7:51
Exactly.
speaker_0HOST
7:52
It's basically designed to ensure that if a country provides a biological resource, they share in the commercial benefits derived from it.
Dennis WalkerHOST
7:16
Iboga from the stewards of this culture over in Gabon and from the Bwidi and would love to hear a little bit about your experience having come from this drug policy background and operating in Tijuana and in Mexican clinics and then all of a sudden going over to meet the the Bwidi and Gabon and learn more about it.
Dennis WalkerHOST
7:35
Can you tell us a little bit about some of your experiences over there, which ultimately I think also has led to Ambio Life Sciences offering the first Nagoya protocol compliant Iboga product, which we can talk about as well.
Jonathan DickinsonGUEST
7:48
Sure.
Jonathan DickinsonGUEST
7:48
Yeah.

39 MINS LATER

Dennis WalkerHOST
47:15
So do a lot of white collar professionals.
Dennis WalkerHOST
47:17
So I just wanted to mention that while I have the attention of the audience at the moment.
Dennis WalkerHOST
47:21
And one other thing I'd really love to jump into is the Nagoya protocol compliance, because, uh, Ibogaine and Iboga are already new enough for the general populace and people are just hearing about this.
Dennis WalkerHOST
47:34
People maybe have, in a lot of cases, no familiarity with psychedelics or international indigenous culture.
Sean McAllisterGUEST
25:57
So that's a built-in colonialism problem.
Sean McAllisterGUEST
26:02
And I certainly support concepts like the Nagoya Protocol that say if you're going to use indigenous technology, you have to give back, you have to have benefit sharing.
Sean McAllisterGUEST
26:13
But to your real question about is there some endangerment from the executive order that we're going to deplete Ibogaine, Or ayahuasca in South America, ibogaine in Gabon.
Sean McAllisterGUEST
26:26
I think there's a lot of uncertainty about this topic.
Sean McAllisterGUEST
29:39
And I think, you know, the question is, can we do it the right way? Colorado, for example, has started a we decriminalized Iboga, but that doesn't make it legal to import into the United States.
Sean McAllisterGUEST
29:54
And now we're talking about adding it to the regulated program.
Sean McAllisterGUEST
29:58
But our advisory board said, we'll only do that if we can bring Iboga here in compliance with the Nagoya protocol.
Sean McAllisterGUEST
30:07
And that's probably going to require a negotiation with the federal government.
Dennis McKennaHOST
29:09
Were you part of that founding or had he already created that by the time you were in Gabon?
Jonathan DickinsonGUEST
29:17
no i watched jan go through the process of founding that and tried to support in whatever way that i could when i became more involved i guess was at a certain point blessings of the forest was granted a mandate by the national parks association to implement the Nagoya Protocol, which was an international treaty that Gabon has tried to use to structure how you could have ethical contracts with traditional communities related to access to iboga, but also traditional knowledge about how iboga can be used.
Jonathan DickinsonGUEST
30:06
And so blessings of the forest was originally contracted to try to implement this, this treaty in Gabon.
Jonathan DickinsonGUEST
30:14
And, uh, I think quite successfully because it's, it's grown and grown in Gabon has done quite a lot of, I would say quite difficult work.
Dennis McKennaHOST
31:27
But there's still a lot of illegal export and poaching and all that.
Dennis McKennaHOST
31:32
And then you, about this same time, you were very concerned to help with this, and you founded Terranosis, which is another NGO.
Dennis McKennaHOST
31:46
And the mission of Terranosis, as I understand it from the book, was basically to... facilitate ability to export iboga root under the Nagoya protocols that's compliant with Nagoya protocols.
Dennis McKennaHOST
32:03
So you've always approached this very ethically, which speaks well of you, recognizing that this is an important traditional medicine.
Rubina MargossianHOST
19:16
Also, his column will be bilingual Armenian.
Rubina MargossianHOST
19:19
And he's kind of looking into international law from his own very interesting perspective.
Rubina MargossianHOST
19:25
But other than that, we also published the translation of one of his articles about the Nagoya Protocols.
Rubina MargossianHOST
19:33
And this is coming up to COP 17.
Rubina MargossianHOST
19:36
And, you know, Armenia is a secretary.
Roubina MargossianHOST
19:16
Also, his column will be bilingual Armenian.
Roubina MargossianHOST
19:19
And he's kind of looking into international law from his own very interesting perspective.
Roubina MargossianHOST
19:25
But other than that, we also published the translation of one of his articles about the Nagoya Protocols.
Roubina MargossianHOST
19:33
And this is coming up to COP 17.
Roubina MargossianHOST
19:36
And, you know, Armenia is a secretary.
Glauber Loures de AssisGUEST
35:57
I think they are very important.
Glauber Loures de AssisGUEST
35:59
and is this going to affect a specific indigenous nation a specific community are we going to take seriously the idea of for example indigenous genocide in the amazon rainforest so if you are just extracting dmt from ayahuasca to offer in a psychedelic assisted therapy we are not aware that this might affect uh the the populations in the amazon rainforest itself uh the other thing uh it's co-production of knowledge so if we already have so many uh synthetic uh possibilities why would people need to bring all these biocultures also to this field without prior informed consent without benefit sharing without and this is an america case without nagoya protocol playing any kind of of roles so these are my concerns and if we are of course uh and this there is a friend of mine then is that uh he developed this concept of molecular colonialism i think this is very provocative but on the other hand uh it's not simply being against it it's just like how are people doing it so i would say and i will uh pass it on to you that more important than the what so we are we are getting some specific molecules and we are working with them to produce a different uh a different medication or a different tool that might support people this is the classic what question what we are doing we are doing this and then if we we ask you if you ask me if I like it or not if I'm in favor or not I would say I I can't tell beforehand.
Glauber Loures de AssisGUEST
37:39
I can only tell when I also know the how.
Glauber Loures de AssisGUEST
37:41
The how question, I think it's more important.
Glauber Loures de AssisGUEST
37:44
How are people doing it? So what kind of people are coming together? What kind of relationship they're developing? What kind of platform? What kind of model to offer to who? To serve who? To escalate in which way? And also to what kind of access they're also bringing to minorities and vulnerable populations.
Glauber Loures de AssisGUEST
38:08
You know what I mean?
Dennis WalkerHOST
38:11
Let's talk about the Nagoya Protocol.
Dennis WalkerHOST
38:13
I think a lot of people still don't know what that is.
Marcelo BeharGUEST
32:21
So this is evolving a lot.
Marcelo BeharGUEST
32:26
The global policies, I would say the Nagoya Protocol, it's a protocol that was built in 2014 and it stands for how we can connect with traditional communities and it has been a challenge to move this forward.
Marcelo BeharGUEST
32:42
I think this year we'll have some elements that will help this to move into a better position.
Marcelo BeharGUEST
32:49
One of these is on the biodiversity co-op meeting in October, the deployment of the Cali Fund, which is a fund diverted to those communities, will be enhanced and probably started.

1 more episode mentions Nagoya Protocol.

Create an account to see the whole feed, search across every transcript, and follow the entities you care about.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.